Novo Nordisk's capital markets day in London turned into a tough room. Shares slid as much as 9% as analysts grilled management on pricing power, dealmaking strategy, and how the company plans to survive looming patent expirations for semaglutide — the active ingredient in both Wegovy and Ozempic — expected in the early 2030s. CEO Mike Doustdar laid out a bold vision: more than five blockbuster drugs by 2030, over 150 billion Danish crowns (~$23B) in pipeline sales by 2035, and 60 million patients globally. Investors weren't convinced.

The skepticism is rooted in a rough few years. Novo's shares have fallen more than 70% from their record highs, and rival Eli Lilly's Zepbound is on track to outsell Wegovy by upwards of $7 billion this year. The company has also shed 13,000 employees — 9,000 through layoffs and 4,000 subsequent exits — as part of a sweeping cost-cutting drive. Novo also detailed a multi-year pipeline rollout, including a CagriSema launch early next year, standalone cagrilintide and high-dose CagriSema in 2028, and simultaneous oral and injectable launches for zenagamtide, while signaling appetite for larger M&A deals beyond small bolt-ons.

By the Numbers:

• Novo shares fell ~9% at peak, recovering to ~4.4% down by midday
• Zepbound on track to outsell Wegovy by >$7 billion this year
• 13,000 total staff departures (9,000 layoffs + 4,000 exits)
• 50% of the Wegovy franchise now via out-of-pocket, self-pay channels
• 7 million oral Wegovy prescriptions in the US to date
• Pipeline sales target: >150 billion DKK (~$23B) by 2035

Why it matters: Novo's capital markets day was meant to reassure investors — instead, it highlighted just how much ground the company needs to recover. With patent cliffs approaching and Lilly pulling ahead, Novo's ability to execute on its next-generation pipeline and M&A strategy will be critical for the future of the obesity drug market.